Natural correction of hyperuricemia, not by allopurinol, could slow down the progression of renal disease in the patient with chronic kidney disease stage 3
Correction of hyperuricemia can slow down the progression of renal disease in animal study. However, there is limited data regarding the effect of lowering serum uric acid in patients with hyperuricemic chronic kidney disease (CKD) stage 3 (estimated GFR [eGFR] 30-60 mL/min). Methods: We retrospecti...
Main Authors: | Kyung Sun Park, Jai Won Chang |
---|---|
Format: | Article |
Language: | English |
Published: |
The Korean Society of Nephrology
2012-06-01
|
Series: | Kidney Research and Clinical Practice |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211913212005505 |
Similar Items
-
Comparison of Febuxostat and Allopurinol in the Treatment of Patients with Chronic Kidney Disease Stage 3∼5 with Hyperuricemia
by: Zhimin Liao, et al.
Published: (2022-01-01) -
Allopurinol reduces cardiovascular risks and improves renal function in pre-dialysis chronic kidney disease patients with hyperuricemia
by: Siren Sezer, et al.
Published: (2014-01-01) -
The effect of allopurinol on the progression of chronic kidney disease
by: Aygul Ozdemir, et al.
Published: (2017-04-01) -
Effect of Febuxostat versus Allopurinol on the Glomerular Filtration Rate and Hyperuricemia in Patients with Chronic Kidney Disease
by: Shankar Prasad Nagaraju, et al.
Published: (2023-01-01) -
Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients
by: Yanchun Li, et al.
Published: (2019-01-01)